Sustained delivery of intact drug to the colon: Mesalamine formulation and temporal gastrointestinal transit analysis

Pharmaceutical Development and Technology

Volumn 14, Issue 1, 2009, Pages 119-128

  Chuong, Monica C ^a   Christensen, J Mark ^b   Ayres, James W ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Colon; Delayed release; Enteric coating; Eudragit ; Explotab; Extrusion; Gastrointestinal transit; Gelucire ; Kollidon ; Mesalamine; Spheronization; Wurster spray coater

Indexed keywords

EUDRAGIT; MESALAZINE;

AREA UNDER THE CURVE; ARTICLE; COLON; CONTROLLED STUDY; DELAYED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; FOOD; INTESTINE TRANSIT TIME; MAXIMUM PLASMA CONCENTRATION; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SPHERONIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCERATIVE COLITIS;

EID: 61649124283     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802420559     Document Type: Article

References (15)

1. Wilson CG. Colonic drug delivery. In: Modified-Release Drug Deliver Technology. NY: Marcel Dekker; 2003:217.
2. Chang G, et al. Time and pH-dependent colon-specific drug delivery for orally administrated diclofenac sodium and 5-aminosalicylic acid. World. J. Gastroenterol. 2004;10(12):1769-1774.
3. Chuong MC, Christensen JM, Ayres JW. Dissolution of mesalamine tablets and capsules Dissolut. Technol. 2008;15(3):7-14, 2008.
4. Rudolph MW, Klein S, Beckert TE, Petereit HU, Dressman JB. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur. J. Pharmaceut. Biopharmaceut. 2001;51:183-190.
5. US Pharmacopeia 31/NF 26. Rockville: USP Convention, Inc., 2008:2630-2632.
6. Zar JH. Biostatistical Analysis. Upper Saddle River: Prentice Hall; 1999:80-81.
7. Bondesen S, Hegnhøj J, Larsen F, Hansen SH, Hansen CP, Rasmussen SN. Pharmacokinetics of 5-aminosalicyclic acid in man following administration of intravenous bolus and per os slow-release formulation. Digest. Dis. Sci. 1991;36(12): 1735-1740.
8. Myers B, Evans DN, Rhodes J, Evans BK, Hughes BR, Lee MG, Richens A, Richards D. Metaboism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196-200.
9. Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment. Pharmacol. Ther. 2004;19:1089-1098.
10. Davis SS, et al. The effect of food on the gastrointestinal transit of pellets and an osmotic device (Osmet). Int. J. Pharmaceut. 1984;21:331-340.
11. Washington N, Washington C, Wilson CG. Physiological Pharmaceutics. NY: Taylor & Francis; 2001:149.
12. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem. 1(4):277-351, 2001. Review.
13. Gibson M. Pharmaceutical Preformulation and Formulation. Boca Raton, FL: Interpharm/CRC 2004:108.
14. Palsmeire RK, Radzik DM, Lunte CE. Investigation of the degradation mechanism of 5-aminosalicylic acid in aqueous solution. Pharmaceut. Res. 1992;9(7):933-938.
15. Kibbe AH. Handbook of Pharmaceutical Excipients. Washington DC: American Pharmaceutical Association and Pharmaceutical Press; 2000:392,433,501-503.